Vaccine Effectiveness, Burden and Impact Studies (VEBIS) of COVID-19 and Influenza – Tender Specifications ECDC/2021/12924  DL 1.4.3. Annual  epidemiological  descriptive and analytical  report (vaccine  effectiveness)  Descriptive and analytical report. Deliverable includes scripts used to create  the analysis report. Cumulative data presented since the beginning of data  collection. Format of the reports to be agreed with ECDC during monthly  conference calls.  The report should include descriptive data on study participants and  recruitment. The descriptive data should also be stratified by vaccine brand  name, site, age group, sex and other relevant variables. Vaccine effectiveness estimates against primary and secondary study outcomes  should also be included by compiling data from each study site and should be  stratified by vaccine brand name, site, age group, sex and other relevant  variables.  On an annual basis  Word - ECDC  template  DL 1.4.4. Draft  manuscript  The contractor shall draft scientific manuscripts to be submitted to peer- reviewed biomedical journals for open access. The topics of manuscripts will be  agreed with ECDC during the monthly conference calls. Manuscripts shall be  approved by ECDC prior to submission.  Once or twice per  year  Word  DL 1.4.5. Scientific  materials for outputs  related to the hospital  network The contractor will prepare presentations or brief summaries upon request of  ECDC on topics relevant to the ECDC Hospital network. Each deliverable  foresees up to three presentations (approximately 15 slides) and two brief  summarises (two pages each).  Content of the presentation/s and supporting document to be agreed with  ECDC during monthly conference calls. Content of data presented to be as up  to date as possible with data that has been validated.  Every three  months  Word – ECDC  Template;  PowerPoint  Task 5: Evaluation of the ECDC hospital network  The contractor is expected to evaluate how the ECDC hospital network is fit for the objectives of the SARI surveillance and for the vaccine effectiveness  studies (e.g. to monitor mainly incidence and trends of severe acute respiratory infections and to provide unbiased estimates of vaccine effectiveness) and  provide a comprehensive report on the evaluation, including recommendations for further improvement of the network.